US 12,186,310 B2
	Antibody-drug conjugate
Takeshi Masuda, Tokyo (JP); Hiroyuki Naito, Tokyo (JP); Takashi Nakada, Tokyo (JP); Masao Yoshida, Tokyo (JP); Shinji Ashida, Tokyo (JP); Hideki Miyazaki, Tokyo (JP); Yuji Kasuya, Tokyo (JP); Koji Morita, Tokyo (JP); Yuki Abe, Tokyo (JP); and Yusuke Ogitani, Tokyo (JP)
Assigned to DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Filed by DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Filed on Mar. 3, 2023, as Appl. No. 18/117,089.
Application 18/117,089 is a continuation of application No. 16/828,279, filed on Mar. 24, 2020, granted, now 11,633,493.
Application 16/828,279 is a continuation of application No. 16/142,354, filed on Sep. 26, 2018, granted, now 10,973,924, issued on Apr. 13, 2021.
Application 16/142,354 is a continuation of application No. 14/435,114, granted, now 10,195,288, issued on Feb. 5, 2019, previously published as PCT/JP2013/006069, filed on Oct. 10, 2013.
Claims priority of application No. 2012-225887 (JP), filed on Oct. 11, 2012.
Prior Publication US 2024/0082413 A1, Mar. 14, 2024
Int. Cl. A61K 47/68 (2017.01); A61K 31/4745 (2006.01); A61K 31/48 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)

CPC A61K 31/4745 (2013.01) [A61K 31/48 (2013.01); A61K 47/68037 (2023.08); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2851 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); C07K 2317/30 (2013.01); C07K 2317/77 (2013.01)]

1 Claim

1. A compound of the following formula: